# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Leonard Nimoy (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML017-SYN
- Date: 2026-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carla Benedetti, MD
- Calendar frame: modern shifted

## Reason for visit

New patient visit for COPD and breathlessness walking any distance. **S**

## Historical basis

- Leonard Nimoy was born in Boston on March 26, 1931. **D**
- He played Mr. Spock in the Star Trek television series from 1966 to 1969, later acted in and directed Star Trek films, and directed other films, including the comedy Three Men and a Baby. **D**
- In a Twitter post at the end of January 2014 he announced that he had chronic obstructive pulmonary disease: "I quit smoking 30 yrs ago. Not soon enough. I have COPD. Grandpa says, quit now!! LLAP". **D**
- In early February 2014 he posted "I'm doing OK. Just can't walk distances," and ABC News reported that he had been seen at an airport in a wheelchair. **D**
- In February 2014 he urged smokers to quit: "Smokers, please understand. If you quit after you're diagnosed with lung damage it's too late." **D**

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Breathlessness keeps him from walking any distance, and he uses a wheelchair at airports. **S**
- Wants other smokers to quit before their lungs are damaged, and wants to keep working on his photography and writing. **S**

## Strengths and supports

- Supports: spouse, adult children, long-time friends and colleagues; wants to use his experience to persuade smokers to quit **S**

## Medications and allergies

- Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) **S**
- Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- about 1984: Former smoker who quit about thirty years before the index visit **D** (CLM-0003)
- January 2014: Chronic obstructive pulmonary disease, disclosed publicly in late January, with breathlessness that keeps him from walking distances **D** (CLM-0003, CLM-0004)

## Procedures and immunizations

- 2026-02-10 to 2026-02-10: Spirometry before and after albuterol 400 mcg: FEV1 1.18 L before and 1.26 L after bronchodilator (46 percent predicted), FVC 2.93 L, FEV1/FVC 0.43 after bronchodilator **S**
- 2026-02-10 to 2026-02-10: 12-lead ECG: sinus rhythm at 84 per minute, normal axis and intervals, no ischemic change or right heart strain **S**
- 2025-10-07: High-dose influenza vaccine, 2025-2026 season **S**
- 2019-04-16: Recombinant zoster vaccine, two-dose series completed **S**
- 2018-05-22: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

FEV1 before bronchodilator: 1.18 L (low); FEV1 after bronchodilator: 1.26 L (low); FEV1 percent predicted after bronchodilator: 46% (low); FVC after bronchodilator: 2.93 L; FEV1/FVC after bronchodilator: 0.43 (low); Blood eosinophil count: 0.18 10*3/uL; Alpha-1 antitrypsin: 138 mg/dL; Hemoglobin: 14.6 g/dL; Creatinine: 0.98 mg/dL; PHQ-9: 3. All results are synthetic.

BP 132/78 mmHg; pulse 84 bpm; respirations 20/min; temperature 36.7 °C; oxygen saturation 93% on room air; weight 80 kg; BMI 23.4 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, articulate, and dryly humorous; asks precise questions about his test results; Mood steady; PHQ-9 score 3; GAD-2 score 1. Functional status: At intake, stops for breath after about 100 meters on level ground (mMRC grade 3); CAT score 22; independent in self-care; After pulmonary rehabilitation, walks about 300 meters at his own pace before stopping (mMRC grade 2); CAT score 15 at three months and 14 at six months. Physical examination is intentionally limited. **S**

## Assessment

1. Chronic obstructive pulmonary disease, GOLD 3 (severe airflow limitation), group B, confirmed on spirometry; synthetic modern classification linked to his publicly disclosed COPD; status draft. **S**
2. Former smoker, quit about 30 years ago through a cessation program; status draft. **S**

## Plan

- Start tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations each morning, keep albuterol as needed, and teach and check inhaler technique at every visit; no inhaled corticosteroid while there are no exacerbations and blood eosinophils are below 300 per microliter. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- Pulmonology consultation to confirm the GOLD grade and group, review the inhaler choice and the place of an inhaled corticosteroid, assess oxygen need at rest and on exertion, interpret the alpha-1 antitrypsin result, and advise on pulmonary rehabilitation and lung cancer screening. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- At every visit: CAT, mMRC, exacerbations in the past 12 months, GOLD group, pulse oximetry, smoking status, BMI, and inhaler technique. Spirometry at diagnosis and at least yearly; alpha-1 antitrypsin once; blood eosinophils at baseline and before any change in inhaled corticosteroid; arterial blood gas only if resting saturation is 92 percent or less; long-term oxygen only for resting saturation of 88 percent or less confirmed twice at least three weeks apart; ECG and cardiovascular risk at baseline. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020) **S**
- Written COPD action plan: what an exacerbation looks like (more breathlessness, more or discolored sputum), when to use extra albuterol, and when to call the clinic the same day or go to emergency care. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- Lung cancer screening reviewed and not offered: he quit smoking more than 15 years ago, so he does not meet the USPSTF criteria despite more than 20 pack-years. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Lung Cancer: Screening (2021) **S**
- Vaccines for COPD: yearly influenza (high dose at 65 and older), PCV20 once, RSV once at 75 and older, COVID-19 by CDC guidance, Tdap every ten years, and recombinant zoster. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Adult Immunization Schedule by Age (2026) **S**
- Comorbidity and mood screening at intake and yearly (depression, anxiety, cardiovascular disease, osteoporosis, reflux, sleep, nutrition), and advance care planning at the wellness visit. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**

## Guideline basis

- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025), Global Initiative for Chronic Obstructive Lung Disease
- CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026), Aether Forge
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (Am J Respir Crit Care Med 2020;202(10):e121-e141)
- Lung Cancer: Screening (2021), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
